PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.44), $0.84 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $45.8 million versus the consensus estimate of $28.78 million.

2017 Guidance:

• Translarna net sales for 2017 are now anticipated to be between $120 and $140 million, an increase from prior guidance of $115 to $130 million. PTC anticipates EMFLAZA net sales for 2017 to be between $15 and $20 million. PTC also anticipates a $20 million milestone payment in 2017 related to the SMA program for total 2017 revenues between $155 and $180 million.
• GAAP operating expenses for the full year 2017 are anticipated to be between $250 to $260 million. Excluding estimated non-cash stock-based compensation expense of approximately $40 million, full year 2017 non-GAAP operating expenses are anticipated to be between $210 million and $220 million. These expenses will be primarily in support of the commercial availability of Translarna globally, the commercial launch of EMFLAZA in the U.S. and the continued research and clinical development of other product pipeline candidates.
• PTC expects to end 2017 with over $120 million of cash and cash equivalents.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.